Pharmaceutical industry ranked one of the highest contributors to UK society
![](/46/pdcnewsitem/07/86/88/Pharmaceutical%20industry%20ranked%20one%20of%20the%20highest%20contributors%20to%20UK%20society.jpeg)
Public perception, however, still falls far below other sectors.
The pharmaceutical industry ranks among the least successful sectors in demonstrating its value to society, a new study by Portland has revealed.
Portland’s inaugural Total Value Index has launched today and measures the value that organisations create for all stakeholders. It looks at nine sectors and uses a wide range of measures including profits and dividends, R&D levels, employee diversity and satisfaction to records on corporate tax and the environment, to assess and rank the total value performance of sectors. It also tests the findings against how an external informed audience thinks the different sectors are doing and why.
The pharmaceutical industry scored consistently low on perceptions for most measures. In real terms, however, Portland’s data found that they industry adds much more value than most sectors, particularly in local investment, strong dividend performance, and the presence of female CEOs. These findings reflect the opportunities for industry to communicate its real terms contribution and close the gap between opinion and reality.
Pharmaceuticals had the largest perception gap of any sector for their role as a producer, demonstrating the greater need for individual companies to explain the life-changing nature of the medicines that they create.
Negative drivers that lowered overall perceptions of the industry included public drug price debates with the NHS, Brexit stockpiling uncertainties, executive pay, and lack of transparency over clinical trials.
Dr Jane Brearley, Senior Partner and Head of Health at Portland, said: “These findings show that the pharmaceutical industry can no longer rely on old narratives of large R&D investment to raise its reputation. To cut-through to payers and the public, individual companies must centre their value story on the life-changing effects of their treatments for patients, and their ability to provide the NHS with the headroom it sorely needs”.
The Total Value Index measures the value brought to society by nine sectors – retail, TMT, banks, automotive, real estate, oil & gas, food, water and pharma.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance